Outcome of COVID-19 in liver transplant recipients: A preliminary report from Northwestern Italy.
Aged
Aged, 80 and over
Antiviral Agents
/ administration & dosage
COVID-19
/ diagnosis
COVID-19 Testing
Drug Therapy, Combination
/ methods
Female
Graft Rejection
/ immunology
Humans
Hydroxychloroquine
/ administration & dosage
Immunocompromised Host
Immunosuppressive Agents
/ adverse effects
Italy
/ epidemiology
Liver Transplantation
/ adverse effects
Male
Middle Aged
SARS-CoV-2
/ immunology
Transplant Recipients
/ statistics & numerical data
COVID-19 Drug Treatment
COVID-19
early infection
immunosuppression
viral carriage
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
10
05
2020
accepted:
27
05
2020
pubmed:
6
6
2020
medline:
16
12
2020
entrez:
6
6
2020
Statut:
ppublish
Résumé
Covid-19 pandemic is deeply affecting transplant activity worldwide. It is unclear whether solid organ transplant recipients are at increased risk of developing severe complications and how they should be managed, also concerning immunosuppression. This is a report about the course and management of SARS-CoV-2 infection in liver transplant recipients from a single center in Northwestern Italy in the period March-April 2020. Three patients who were treated at our institution are reported in detail, whereas summary data are provided for those managed at peripheral Hospitals. Presentation varied from asymptomatic to rapidly progressive respiratory failure due to bilateral interstitial pneumonia. Accordingly, treatment and changes to immunosuppression were adapted to the severity of the disease. Overall mortality was 20%, whereas Covid-related mortality was 10%. Two cases of prolonged (>2 months) viral carriage were observed in two asymptomatic patients who contracted the infection in the early course after transplant. Besides depicting Covid-19 course and possible treatment scenarios in liver transplant patients, these cases are discussed in relation to the changes in our practice prompted by Covid-19 epidemic, with potential implications for other transplant programs.
Identifiants
pubmed: 32500942
doi: 10.1111/tid.13353
pmc: PMC7300527
doi:
Substances chimiques
Antiviral Agents
0
Immunosuppressive Agents
0
Hydroxychloroquine
4QWG6N8QKH
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13353Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Am J Transplant. 2020 Jul;20(7):1849-1858
pubmed: 32301155
Am J Transplant. 2020 Jul;20(7):1780-1784
pubmed: 32243677
Hepatology. 2020 Oct;72(4):1491-1493
pubmed: 32220017
Arch Pathol Lab Med. 2020 Apr 17;:
pubmed: 32302212
Liver Transpl. 2020 Jun;26(6):832-834
pubmed: 32196933
Lancet Infect Dis. 2018 Aug;18(8):e217-e227
pubmed: 29680581
Transpl Infect Dis. 2020 Oct;22(5):e13353
pubmed: 32500942
Am J Transplant. 2020 Jul;20(7):1939-1940
pubmed: 32181969
Am J Transplant. 2020 Jul;20(7):1840-1848
pubmed: 32330351
Am J Transplant. 2020 Jul;20(7):1800-1808
pubmed: 32330343
Am J Transplant. 2020 Jul;20(7):1768-1772
pubmed: 32090448
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508